Canadian Prostate Brachytherapy in 2012

Keyes, Mira; Crook, Juanita; Morris, William; Morton, Gerard; Pickles, Tom; Usmani, Nawaid; Vigneault, Éric

doi:10.5489/cuaj.218

Cited by 23 publications

(15 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The response rate to this survey was excellent; 15 of 17 departments practising HDR‐PB in Australia and New Zealand provided full responses. Unlike previously published brachytherapy patterns of care surveys, this work focussed specifically on aspects of the treatment delivery technique and routine practice of HDR‐PB . The authors of this survey are not aware of any other surveys of this scale that target HDR‐PB equipment and processes.…”

Section: Discussionmentioning

confidence: 99%

Survey of high‐dose‐rate prostate brachytherapy practice in Australia and New Zealand, 2010–2011

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Survey of high‐dose‐rate prostate brachytherapy practice in Australia and New Zealand, 2010–2011

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Permanent brachytherapy using radioactive seeds is an efficacious treatment for prostate cancer due to its excellent success rates, favourable toxicity profile, and non-invasiveness [3]. This procedure delivers radiation to tumours by implanting radioactive seeds in close proximity to the tumour or within the tumour itself by means of long hollow, seed-carrying needles.…”

Section: Introductionmentioning

confidence: 99%

A Hand-Held Assistant for Semiautomated Percutaneous Needle Steering

Rossa

Usmani

Sloboda

et al. 2017

IEEE Trans. Biomed. Eng.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The literature has reported that each specialist is more likely to recommend treatment that they provide. 4 In anticipation for an increase in the number of PCa diagnoses in the coming years, an understanding of the decision-making process is exceedingly important. 1,5 In 2007, the Gale and Graham Wright Prostate Centre (GGWPC), in collaboration with the Odette Cancer Centre (OCC), was established at North York General Hospital (NYGH).…”

Section: Introductionmentioning

confidence: 99%

Diagnosis, referral, and primary treatment decisions in newly diagnosed prostate cancer patients in a multidisciplinary diagnostic assessment program

Guy

Ghanem

Loblaw

et al. 2016

CUAJ

Self Cite

View full text Add to dashboard Cite

Introduction: We aimed to report on data from the multidisciplinary diagnostic assessment program (DAP) at the Gale and Graham Wright Prostate Centre (GGWPC) at North York General Hospital (NYGH). We assessed referral, diagnosis, and treatment decisions for newly diagnosed prostate cancer (PCa) patients as seen over time, risk stratification, and clinic type to establish a deeper understanding of current decision-making trends. Methods: From June 2007 to April 2012, 1277 patients who were diagnosed with PCa at the GGWPC were included in this study. Data was collected and reviewed retrospectively using electronic patient records. Results: 1031 of 1260 patients (81.8%) were seen in a multidisciplinary clinic (MDC). Over time, a decrease in low-risk (LR) diagnoses and an increase intermediate-risk (IR) diagnoses was observed (p<0.0001). With respect to overall treatment decisions 474 (37.1%) of patients received primary radiotherapy, 340 (26.6%) received surgical therapy, and 426 (33.4%) had conservative management; 57% of patients who were candidates for active surveillance were managed this way. No significant treatment trends were observed over time (p=0.8440). Significantly, different management decisions were made in those who attended the MDC compared to those who only saw a urologist (p<0.0001). Conclusions: In our DAP, the vast majority of patients presented with screen-detected disease, but there was a gradual shift from low-to intermediate-risk disease over time. Timely multidisciplinary consultation was achievable in over 80% of patients and was associated with different management decisions. We recommend that all patients at risk for prostate cancer be worked up in a multidisciplinary DAP. IntroductionIn 2015, an estimated 24 000 men in Canada will be diagnosed with prostate cancer (PCa) and will need to decide between a variety of management options.1 For many, this can be distressing and lead to post-treatment regret and worse quality of life.2,3 Most commonly, a patient diagnosed with PCa will meet with their urologist to learn about management options. Sometimes a referral for consultation with a radiation oncologist is made. The literature has reported that each specialist is more likely to recommend treatment that they provide. 4 In anticipation for an increase in the number of PCa diagnoses in the coming years, an understanding of the decision-making process is exceedingly important. 1,5 In 2007, the Gale and Graham Wright Prostate Centre (GGWPC), in collaboration with the Odette Cancer Centre (OCC), was established at North York General Hospital (NYGH). As a diagnostic assessment program (DAP), the goal is to improve timely access and the quality of care provided to men with PCa. Our group has already shown that wait times from suspicion to radiation treatment is, on average, two months shorter in the GGWPC vs. standard community practice (183 vs. 138 days, p=0.046). 6Patients are referred from general practitioners or community urologists if they have an elevated prostate-specific antig...

show abstract

Canadian Prostate Brachytherapy in 2012

Cited by 23 publications

References 43 publications

Survey of high‐dose‐rate prostate brachytherapy practice in Australia and New Zealand, 2010–2011

Survey of high‐dose‐rate prostate brachytherapy practice in Australia and New Zealand, 2010–2011

A Hand-Held Assistant for Semiautomated Percutaneous Needle Steering

Diagnosis, referral, and primary treatment decisions in newly diagnosed prostate cancer patients in a multidisciplinary diagnostic assessment program

Contact Info

Product

Resources

About